A Cost-Effectiveness Model to Determine Ostomy-Related Costs of Care and Health Outcomes Among People With an Ostomy in Canada Using a Ceramide-Infused Skin Barrier.
Kimberly LeBlanc, Stephanie Furtado, Deborah Mings and 4 others
PMID 36640162WHAT IT FOUND
A ceramide-infused ostomy skin barrier was modeled to potentially save Can$443.13 per year in Ontario and Can$243.84 in Alberta, with fewer simulated peristomal skin complications.
Key findings
01The Ontario model projected a potential ostomy-related cost saving of Can$443.13 per user per year for the ceramide-infused barrier compared with standard care.
02The Alberta model projected a potential ostomy-related cost saving of Can$243.84 per user per year for the ceramide-infused barrier compared with standard care.
03The model projected fewer total peristomal skin complication events with the ceramide-infused barrier than standard care in Ontario (215 vs 297) and Alberta (875 vs 1208).
STILL TO COME
How it was doneWhat they foundWhat it means for RNs
Read the rest of this summary
You get three full summaries a month, free, and we do not ask for a card. Search, the TL;DRs and your library stay unlimited either way.
What it does not show
This was a hypothetical cost-effectiveness model, not a study of real patients using real ostomy barriers. The model estimated pouch changes and supply use, and the authors state they could not track usage in Ontario. The model allowed up to 2 peristomal skin complications per year, and the authors state this estimate is not based on strong evidence. The cost savings depend on assumed product mix, accessory use, and provincial funding rules, so they may not apply to other provinces or patients. The quality-adjusted life day values are model estimates, not measured patient-reported outcomes.
Declared interests
The paper does not report a funding source or conflict-of-interest declaration. The model used historic database information from Hollister Incorporated and an example Ontario retailer, ALBA Medical.
The easy way to misread this
Do not read the Can$443.13 and Can$243.84 figures as proven savings for a patient, or the lower simulated complication counts as proof that the barrier prevents skin problems. The study used hypothetical cohorts and estimated supply use and complication rates.